Posted on by Cynthia Johnson

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

NCT#: & LinkNCT02912949
NCT QR Code
Available as of:July 15 2024
Contract:Caris
Indication Category:Solid Tumors
Study Sponsor:Merus N.V.
Protocol #:MCLA-128- CL01
Title:A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
Highlight Details:***REFERRAL ONLY*** A Study of Zenocutuzumab (MCLA- 128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
Biomarkers:NRG1 fusions
Indication:Solid tumors 
Phase:2
Treatment Line:
Study Drug/Test Compound:MCLA-128
Notes
Recruitment Status:Just In Time
Participating Institution:Salinas Valley Health
Salinas Valley Health Clinical Research Program:Terri Nielsen, MSJ, RN, CCRP, Clinical Research Program Manager, [email protected]